Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|April 22, 2024
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trialsAndreas Roller, Iakov I Davydov, Petra C Schwalie, et al.Cancer Discovery|March 17, 2018
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of CancerWilliam Pao, Chia-Huey Ooi, Fabian Birzele, et al.European Journal of Cancer (Oxford, England : 1990)|June 6, 2022
Immune contexture of paediatric cancersMeghna Das Thakur, Carl J Franz, Laura Brennan, et al.The Journal of Experimental Medicine|February 14, 2018
Rapid activation of tumor-associated macrophages boosts preexisting tumor immunitySabine Hoves, Chia-Huey Ooi, Carsten Wolter, et al.Journal for Immunotherapy of Cancer|March 24, 2017
Systematic evaluation of immune regulation and modulationDavid F Stroncek, Lisa H Butterfield, Michael A Cannarile, et al.Journal for Immunotherapy of Cancer|December 16, 2020
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II-practical challengesAlessandra Cesano, Michael A Cannarile, Sacha Gnjatic, et al.Journal for Immunotherapy of Cancer|October 31, 2020
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challengesSergio Rutella, Michael A Cannarile, Sacha Gnjatic, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patientsJean-Pascal Machiels, Carlos Gomez-Roca, Jean-Marie Michot, et al.Oncotarget|August 11, 2016
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumorsC Willemien Menke-van der Houven van Oordt, Carlos Gomez-Roca, Carla van Herpen, et al.The Lancet. Oncology|July 17, 2015
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 studyPhilippe A Cassier, Antoine Italiano, Carlos A Gomez-Roca, et al.Pageof 3